Verwiel Frank 4

What Happened Frank Verwiel, a director of Intellia Therapeutics (NTLA), received awards covering a total of 22,500 shares on June 9, 2026. The filing shows two awards: 9,200 restricted stock units (RSUs) that each represent a contingent right to one share, plus a 13,300-share derivative award described in the filing as an option. Both awards were granted at a $0 acquisition price, so there was no cash paid by the insider; aggregate acquisition value reported is $0.

Key Details

• Transaction date: June 9, 2026; Form 4 filed June 10, 2026 (timely).
• Awards: 9,200 RSUs (F1) and 13,300-share derivative option (F2); total 22,500 shares.
• Price: $0.00 per share; reported acquisition value = $0.
• Vesting/terms: 9,200 RSUs are contingent rights to receive one share per unit (F1). The 13,300-share option vests in full on the earlier of (a) the first anniversary of the grant or (b) the next annual stockholders’ meeting (F2).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: appears timely (filed the business day after the grant); no late-filing flag noted.

Context These awards are compensation-related grants to a director rather than open-market purchases or sales. RSUs/options granted at $0 are commonplace as equity compensation and do not by themselves indicate buying or selling sentiment. For the derivative award, vesting is time- or event-based (one year or next annual meeting)—the insider will only receive/control the shares if vesting conditions are met.